This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kala Pharmaceuticals, Inc.
Drug Names(s): acyclovir MPP, acyclovir
Acyclovir-MPP uses Kala’s mucosal penetrating product (MPP) technology coupled with acyclovir to optimize the size and surface coating properties to improve drug penetration and retention in mucosal tissues leading to the potential for enhanced therapeutic outcomes. Preclinical studies demonstrated that MPPs improve mucus penetration and drug retention, enabling the acyclovir-MPP to achieve greater efficacy at one tenth of the dose compared to conventional acyclovir.
Acyclovir is a nucleotide analogue. Its inhibitory activity is highly selective due to its affinity for the enzyme thymidine kinase encoded by herpes simplex and varicella-zoster viruses. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted by other enzymes to acyclovir triphosphate, which stops replication of herpes viral DNA through competitive inhibition of viral DNA polymerase, incorporation into and termination of the growing viral DNA chain, and inactivation of the viral DNA polymerase.
Additional information available to subscribers only: